Aarti Pharmalabs Limited engages in the development of Active Pharmaceutical Ingredients (API) and New Chemical Entities (NCE), API intermediates, Regulatory Starting Materials (RSM), Basic Starting Materials, Key Building Blocks, and Xanthine Derivatives for use in clinical testing and commercial production. In addition to process R&D, we provide stability studies, scale-up and process optimisation, process validations, and commercial manufacturing.
Our six manufacturing plants receive innovations from our two R&D centres. These cutting-edge manufacturing facilities have received accreditation from a number of agencies, including the USFDA, EU GMP, EDQM, KFDA, and COFEPRIS.
This enables APL to deliver our entire range of services to our international clientele for their needs in API and drug substance manufacturing in India.
Sustainability has been deeply integrated with our business strategy. Our highly skilled team delivers innovative solutions consistently by utilising advanced technologies with continuous improvement and operational excellence.